ASX Share rice
Fri 14 May 2021 - 07:38:pm (Sydney)

NOX Share Price

NOXOPHARM LIMITEDNOXPharmaceuticals, Biotechnology & Life Sciences

NOX Company Information


Noxopharm Limited





GIC Industry:


GIC Sub Industry:



828 Pacific Highway Gordon NSW Australia 2072


61 2 9144 2223

Founder, CEO, MD & Director:

Dr. Graham Edmund Kelly

Company Sec.:

Mr. David James Franks B.Ec, BEc, CA, F Fin, JP.

Chief Financial Officer:

Mr. Shawn Van Boheemen

Chief Operating Officer:

Ms. Jeanette Bell

Chief Scientific Officer:

Dr. John Wilkinson

Chief Medical Officer:

Dr. Gisela Mautner

Company Overview:

Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It primarily develops Veyonda, an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also focuses on developing NYX-330, a PCSK9-inhibitor and LDL-cholesterol-lowering drug; NYX-104, a neuroprotectant that protects the brain from further damage after stroke and traumatic brain injury; and NYX-205, an anti-inflammatory drug for the treatment of nerve tissue inflammation. In addition, it develops anti-autoimmune drugs, such as IRAK4 and TPL2 inhibitors; and LuPIN for the combined therapy of Veyonda and 177Lu-PSMA-617. Noxopharm Limited has a partnership with Hudson Institute of Medical Research and a collaboration with The Australian National University to develop a better treatment for septic shock. The company was incorporated in 2015 and is based in Gordon, Australia.

NOX Share Price Information

Shares Issued:


Market Capitalisation:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Profit Margin:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


NOX CashFlow Statement

CashFlow Date:




Change To Liabilities:


Total Cashflow From Investing Activities:


Net Borrowings:


Net Income:


Total Cash From Operating Activities:




Other Cashflow From Investing Activities:


Change To Inventory:


Change To Account Receivables:


Sale Purchase Of Stock:


Capital Expenditures:


NOX Income Statement

Income Date:


Income Before Tax:


Net Income:


Operating Income:


Interest Expense:


Total Revenue:


NOX Balance Sheet

Balance Sheet Date:


Total Liabilities:


Total Stockholder Equity:


Total Assets:


Common Stock:


Other Current Assets:


Retained Earnings:


Other Liabilities:


Other Assets:




Total Current Liabilities:


Short-Term Debt:


Property - Plant & Equipment:


Net Tangible Assets:


Long-Term Investments:


Total Current Assets:


Net Receivables:


Short-Term Investments:




Accounts Payable:


Non Currrent Assets (Other):


Short-Term Investments:


Non Current Liabilities Total:


NOX Share Price History

NOX News

11 May, 2021
Noxopharm begins first-line sarcoma treatment testing for Veyonda.
27 Apr, 2021
Interim data in the NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with COVID-19.
14 Apr, 2021
Noxopharm files septic shock treatment patent for Veyonda®
18 Mar, 2021
Noxopharm Limited announced Veyonda has been approved to move into the second and final stage of the NOXCOVID-1 clinical trial.
17 Feb, 2021
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
03 Dec, 2020
Noxopharm announces a discovery by Cornell Medical College published in Nature Immunology validating the novel DARRT anti-cancer treatment of Veyonda®
12 Nov, 2020
Noxopharm announces pilot study with Bristol Myers Squibb’s product
10 Sep, 2020
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
23 Jul, 2020
Noxopharm has claimed a breakthrough in the search for restoring immune function within "cold" microtumors, converting them to so-called "hot" tumors.